Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efocipegtrutide SAD in healthy obese subjects
NCT03374241Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Sep 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efocipegtrutide in obesity (5 cohorts), sponsored by Hanmi Pharmaceutical. Primary endpoint: Number of Participants With Adverse Events at 1 month. Started Apr 2018; status: completed.
02
Drugs
efocipegtrutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03374241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374241.